AI SUMMARY — The poster presents a bullish case for Evotec (EVO), a European biotech/CRO company, citing undervaluation and potential catalysts. Key risks include execution risk on pipeline programs, competitive pressures in the CRO industry, and potential market sentiment shifts toward European equities.
| TICKER | EVO |
USER | u/Short_Sir_5489 |
| RATING |
BULLISH |
ENTRY |
$1.66
|
| POSITION |
6024 sh
SYN
|
BOOK VAL |
$9969.88 |
| CURRENT |
$1.66 |
P&L % |
+0.30%
|
| CURR VAL |
$10000.00 |
P&L $ |
+30.12
|